Polen - polsk - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

zakłady farmaceutyczne polpharma s.a. - baclofenum - tabletki - 25 mg

Polen - polsk - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

zakłady farmaceutyczne polpharma s.a. - baclofenum - tabletki - 10 mg

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

zaklady farmaceutyczne polpharma sa, starogard gdański array - 1775 baklofen - tableta - 10mg - baklofen

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

zaklady farmaceutyczne polpharma sa, starogard gdański array - 1775 baklofen - tableta - 25mg - baklofen

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

polpharma s.a. - baclofen -

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

polpharma s.a. - baclofen -

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - baclofeno - comprimido - 25 mg - baclofeno 25 mg - baclofen - genérico - duração do tratamento: longa duração

Israel - engelsk - Ministry of Health

cts ltd - baclofen - solution for infusion - baclofen 0.5 mg / 1 ml - baclofen - baclofen sintetica is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic agents and/or those patients who experience unacceptable side effects at effective oral doses.baclofen sintetica is effective in adult patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident; however, clinical experience is limited.paediatric population: baclofen sintetica indicated in patients aged 4 to <18 years with severe chronic spasticity of cerebral origin or of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen 10 mg - baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. the efficacy of baclofen in stroke, cerebral palsy, and parkinson's disease has not been established and, therefore, it is not recommended for these conditions. hypersensitivity to baclofen.

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - baclofen (unii: h789n3fke8) (baclofen - unii:h789n3fke8) - baclofen 10 mg - baclofen tablets usp are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. baclofen tablets usp may also be of some value in patients with spinal cord injuries and other spinal cord diseases. baclofen tablets usp are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. the efficacy of baclofen in stroke, cerebral palsy, and parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. hypersensitivity to baclofen.